Eli Lilly (NYSE: LLY) saw its shares close down 6.6% at $744.91 yesterday, after it revealed forecast for sales at the JP Morgan Healthcare Conference.
The US pharma major said that it expects 2024 full-year worldwide revenue to be around $45.0 billion, which represents growth of 32% compared to the previous year. The company also shared 2025 revenue guidance, anticipating sales will be between $58.0 billion and $61.0 billion.
For the fourth quarter of 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to the like 2023 quarter. This includes about $3.5 billion for diabetes drug Mounjaro (tirzepatide) and $1.9 billion for obesity treatment Zepbound (tirzepatide). In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and neuroscience medicines in fourth-quarter 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze